Close Menu

Yourgene

Premaitha said it has sold more than 17,000 of the tests, which is the focus of an ongoing patent-infringement suit, since its launch in early 2015.

During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.

A UK court accepted an application by Premaitha to include an antitrust claim in its defense, and has tentatively scheduled the trial for the summer of 2017. 

The agreement marks the sixth Iona distribution deal Premaitha has signed with regional partners in recent months, including ones in France and India.

St. George's University Hospitals NHS Foundation Trust, which has been offering NIPT since last year, plans to double its capacity by the third quarter.

Visional Medical will begin offering the test, which estimates the risk of a fetus being affected by Down syndrome and other genetic conditions, in India.

The recommendation calls for NIPT to be initially offered to women deemed at high risk for trisomy 21, 13, or 18 after the initial screening test.

The company has sued three companies in the UK and two in Poland alleging they infringed on the firm's non-invasive prenatal testing patents.

Thermo will invest £5 million in Premaitha as a secured loan facility, of which the firm will receive £3 million initially and the remainder as milestone payments.

Adgenix has already signed up its first laboratory customer, inking a contract for a minimum of three years to supply LaboSud with the assay.

Pages

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.